Ann: Notice of Meeting, page-13

First 13 Last

Share
Profile

Follow
sweety123

1,331 Posts.

28/03/17

01:50

Post #: 23664372
Share

Originally posted by SuperWealthy ↑

Serena I know I've disagreed with you quite vocally on numerous times here but I'll certainly admit that I was wrong about ERJ surviving admin. After 25yrs in this game I've not seen it turned around like this especially as the ERJ balance sheet looked so bad.

I only invested "play money" amounts at 0.005 and had kissed it goodbye.

However I would like to sound a reality check for all those peeps with a big stack of cash in ERJ. I'm not trying to be patronising or an R-sole but some of us need to hear this:

Holders of ERJ just got very, very lucky. It was a super risky gamble to heavily invest in something with such an awful balance sheet, high debt and general inability to get business done. There was much regret about this when ERJ went into admin.

I would encourage all holders to learn from this, don't start dreaming of a 10c or 20c share price or getting greedy. Some holders should simply be planning to pop the parachute and get out with anything close to the original investment intact. We would have jumped at that late last year.

Please don't make the mistake of passing up the chance to take your money off the table, and then still be sitting in ERJ when the poo flies again. Just remember if stock comes out of escrow in 1-2 yrs it only needs a share price of 0.002 for the insiders to make 100%.

Expand

What are your thoughts on open ? Are you thinking of selling ?

VPR Price at posting: 0.5¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 11 more messages in this thread...

First 13 Last

Add VPR (ASX) to my watchlist

(20min delay)
Last 0.2¢		Change 0.000(0.00%)		Mkt cap ! $16.07M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
46	55096344	0.1¢

Sellers (Offers)

Price($)	Vol.	No.
0.2¢	83118455	37

View Market Depth

No.	Vol.	Price($)
46	55096344	0.001
0	0	0.000
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.002	83118455	37
0.003	44374651	27
0.004	32401341	19
0.005	21323846	6
0.006	33329999	5

Last trade - 13.46pm 07/10/2024 (20 minute delay)

VPR (ASX) Chart

Day chart unavailable

Ann: Notice of Meeting, page-13

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Notice of Meeting, page-13

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News